Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes Track

Development of a novel reagent for radiolabeling of peptides and proteins

Krishan Kumar, Karen Woolum and Michael Knopp
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 911;
Krishan Kumar
1Ohio State University Powell OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Woolum
3Wright Center of Innovation in Biomedical Imaging, Department of Radiology The Ohio State University Columbus OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Knopp
2The Ohio State University Columbus OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

911

Objectives: Radiolabeling of a tyrosine residue in peptides and proteins is routinely performed by using various oxidizing agents such as Chloramine T, Iodobeads, and Iodogen reagent and radioactive iodide (I-). The objective of the present study was to develop a novel reagent for radiolabeling of peptides and proteins.

Methods: An inorganic monochloramine (NH2Cl) was investigated as a novel reagent for radiolabeling of a tyrosine residue in peptides and proteins. A known amount of carrier-free 125I Na activity was added to a 100 µL of 0.1 M Sodium Phosphate (pH 7.4) buffer solution containing a known amount of tyrosine amino acid or a cyclic peptide (cRGDyK, cyclo Arg-Gly-Asp-d-Tyr-Lys) or a protein (BSA, Bovine Serum Albumin) in a 1.5 mL Eppendorf centrifuge tube. Excess NH2Cl in PBS buffer was added next and the reaction mixture was incubated at room temperature for 20 minutes. Excess NH2Cl was reduced by the addition of sodium metabisulfite. The crude reaction mixture was purified by using either a Sep-PaK C18 Light cartridge or a PD-10 column. The final product was analyzed by a Reversed-Phase High Performance Liquid Chromatography (RP-HPLC) analytical method.

Results: The RP-HPLC and Matrix-Assisted Laser Desorption Ionization (MALDI) mass spectral analysis of cold iodinated Tyrosine and cRGDyK suggested the formation of mono and diiodinated Tyrosine and cRGDyK. Radiolabeling efficiency (i.e., incorporation of 125I label) were: 100% for Tyrosine, 86% for cRGDyK, and 82% for BSA. Reversed-Phase (for radiolabeled Tyrosine and cRGDyK) and Size-Exclusion (for radiolabeled BSA) HPLC analysis showed >99% Radiochemical Purity (RCP) of the radiolabeled materials.

Conclusion: A novel reagent for radiolabeling of peptides and proteins was developed successfully. Research Support:

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 58, Issue supplement 1
May 1, 2017
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Development of a novel reagent for radiolabeling of peptides and proteins
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Development of a novel reagent for radiolabeling of peptides and proteins
Krishan Kumar, Karen Woolum, Michael Knopp
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 911;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Development of a novel reagent for radiolabeling of peptides and proteins
Krishan Kumar, Karen Woolum, Michael Knopp
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 911;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes Track

  • Synthesis and preliminary biological evaluation of a novel P2X7R radioligand [18F]IUR-1601
  • In vivo evaluation of [225Ac]Ac-DOTAZOL for α-therapy of bone metastases
  • Case study: Evaluating the new University of Florida hybrid pediatric phantoms and tissue weighting factors from ICRP Publication 103 for diagnostic dosimetry
Show more Molecular Targeting Probes Track

Preclinical Probes for Cardiovascular, Endocrine & Other Posters

  • Radiosynthesis of b-phenylethylamine derivatives for cardiac sympathetic nervous PET imaging
  • Feasibility and potentials of thymidine phosphorylase (TP) as an imaging biomarker and its nuclear medicine imaging for the diagnosis of non-alcoholic steatohepatitis
  • Synthesis and characterization of an 18F-labeled AmBF3-conjugated albumin-binding peptide for imaging blood pool by PET/CT
Show more Preclinical Probes for Cardiovascular, Endocrine & Other Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire